OCEAN(a)-PreEvent - Olpasiran Trials of Cardiovascular Events And LipoproteiN(a) Reduction to Prevent First Major Cardiovascular Events

a study on Cardiovascular Disease Heart Disease Heart Attack

Summary

Eligibility
for people ages 50-105 (full criteria)
Location
at La Jolla, California and other locations
Dates
study started
study ends around

Description

Summary

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp[a]).

Official Title

A Double-blind, Randomized, Placebo-controlled, Multicenter Study Assessing Olpasiran Use to Prevent First Major Cardiovascular Events in Participants With Elevated Lipoprotein(a)

Keywords

Cardiovascular Disease, Olpasiran, AMG 890, Coronary heart disease, CHD, Myocardial infarction, Coronary revascularization, Cardiovascular Diseases, Coronary Disease

Eligibility

You can join if…

Open to people ages 50-105

You CAN'T join if...

  • Prior acute atherothrombotic event (myocardial infarction, stroke, transient ischemic attack, acute limb ischemia)
  • Prior or planned arterial revascularization
  • History of major bleeding disorder

Locations

  • University of California San Diego accepting new patients
    La Jolla California 92037 United States
  • Alliance Clinical Research accepting new patients
    San Diego California 92120 United States
  • Encompass Clinical Research accepting new patients
    Spring Valley California 91978 United States
  • Blue Coast Cardiology accepting new patients
    Vista California 92083 United States

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Amgen
Links
AmgenTrials clinical trials website
ID
NCT07136012
Phase
Phase 3 research study
Study Type
Interventional
Participants
Expecting 11000 study participants
Last Updated
Contact us about this trial